Movetis's constipation drug Resolor debuts in Germany
This article was originally published in Scrip
Movetis has launched its lead product Resolor (prucalopride) film-coated tablets in Germany – its first market – for the symptomatic treatment of chronic constipation in women for whom laxatives fail to work. The product was approved in the EU in October.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.